| Index | — | P/E | — | EPS (ttm) | -0.52 | Insider Own | — | Shs Outstand | 639.66M | Perf Week | -11.23% |
| Market Cap | 1.06B | Forward P/E | 2.23 | EPS next Y | 0.74 | Insider Trans | -0.47% | Shs Float | 334.66M | Perf Month | 12.16% |
| Enterprise Value | 5.08B | PEG | — | EPS next Q | 0.18 | Short Float | 13.98% | Perf Quarter | -15.74% | ||
| Income | -334.00M | P/S | 0.44 | EPS this Y | 11.89% | Short Ratio | 10.21 | Perf Half Y | -40.93% | ||
| Sales | 2.41B | P/B | 0.23 | EPS next Y | 1.16% | ROA | -3.19% | Short Interest | 46.78M | Perf YTD | -50.30% |
| Book/sh | 7.09 | P/C | 4.87 | EPS next 5Y | 5.75% | ROE | -7.00% | 52W High | 3.87 -45.99% | Perf Year | -48.77% |
| Cash/sh | 0.34 | P/FCF | 3.24 | EPS past 3/5Y | — | ROIC | -0.92% | 52W Low | 1.42 47.18% | Perf 3Y | -74.42% |
| Dividend Est. | — | EV/EBITDA | 7.61 | Sales past 3/5Y | -2.64% 14.38% | Gross Margin | 66.82% | Volatility | 6.73% 5.76% | Perf 5Y | -92.74% |
| Dividend TTM | — | EV/Sales | 2.11 | EPS Y/Y TTM | — | Oper. Margin | -3.51% | ATR (14) | 0.10 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 0.85 | Sales Y/Y TTM | -3.48% | Profit Margin | -13.84% | RSI (14) | 42.12 | Recom | 2.90 |
| Dividend Gr. 3/5Y | — | Current Ratio | 0.85 | EPS Q/Q | 5.56% | SMA20 | -2.38% | Beta | 1.35 | Target Price | 2.00 |
| Payout | 0.00% | Debt/Eq | 0.93 | Sales Q/Q | -5.48% | SMA50 | -8.48% | Rel Volume | 1.05 | Prev Close | 1.66 |
| Employees | 12,000 | LT Debt/Eq | 0.93 | Earnings | Nov 03 | SMA200 | -25.16% | Avg Volume | 4.05M | Price | 2.09 |
| IPO Date | Oct 29, 2018 | Option/Short | No / Yes | EPS/Sales Surpr. | 4.96% -0.41% | Net Debt/EBITDA | 6.02 | Volume | 4,253,344 | Change | 25.90% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-30-26 | Reiterated | Barclays | Underweight | $2.50 → $2.00 |
| Jul-07-26 | Reiterated | Barclays | Underweight | $2.50 |
| Jan-08-26 | Downgrade | Goldman Sachs | Buy → Neutral | $4.20 → $3.60 |
| Dec-17-25 | Downgrade | Morgan Stanley | Equal Weight → Underweight | $3.00 |
| Oct-30-25 | Reiterated | Goldman Sachs | Buy | $4.80 → $4.20 |
| Jul-18-25 | Downgrade | Jefferies | Buy → Hold | |
| Nov-06-24 | Downgrade | William Blair | Outperform → Market Perform | |
| Dec-15-23 | Downgrade | Wells Fargo | Equal Weight → Underweight | |
| Sep-08-23 | Downgrade | Barclays | Equal Weight → Underweight | |
| Aug-25-23 | Downgrade | RBC Capital | Outperform → Sector Perform |
Clarivate Plc operates as a prominent information services and analytics firm, furnishing structured data and insights. Its core mission is to facilitate the discovery, safeguard the intellectual property, and enable the commercialization of scientific research, innovations, and established brands. The company's portfolio includes the extensive Web of Science suite, a collection of essential tools such as Web of Science, InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio. These are designed to support organizations throughout the entire research lifecycle, from initial planning and funding to execution and utilization. Within the Life Sciences domain, Clarivate provides specialized products like Cortellis and Newport Integrity. These platforms cater to pharmaceutical and biotechnology companies, empowering their research endeavors, supplying vital market intelligence, and facilitating competitive monitoring during the development and launch phases of novel drugs. Its Derwent product line, comprising Derwent Innovation, Techstreet, and IP Professional Services, is dedicated to intellectual property management. These tools enable customers to evaluate the originality of potential products, establish their freedom to operate within design parameters, secure patent protection, analyze the competitive technological landscape, and ensure adherence to essential industry standards. Complementing these, CompuMark delivers trademark screening, search, and monitoring solutions vital for businesses and legal firms. Meanwhile, MarkMonitor empowers enterprises to establish, manage, optimize, and fortify their digital presence. Clarivate's diverse clientele spans government agencies, academic institutions, life science enterprises, and research and development corporations worldwide, with operations across the Americas, Middle East, Africa, Europe, and Asia Pacific regions. The company, initially known as Clarivate Analytics Plc, rebranded to Clarivate Plc in May 2020. It maintains its headquarters in London, United Kingdom.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,413 | 2,455 | 2,557 | 2,629 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 801 | 834 | 869 | 906 | — | — | — | — | — | |
| Gross Profit | 1,612 | 1,622 | 1,688 | 1,722 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 707 | 709 | 728 | 740 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | 990 | 841 | 1,235 | 1,717 | — | — | — | — | — | |
| Operating Income | -85 | 72 | -276 | -735 | — | — | — | — | — | |
| Interest Expense | 254 | 265 | 283 | 294 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 0 | 0 | 5 | 16 | — | — | — | — | — | |
| Net Income Before Taxes | -339 | -194 | -554 | -1,012 | — | — | — | — | — | |
| Income Taxes | -5 | 7 | 83 | -101 | — | — | — | — | — | |
| Consolidated Net Income | -334 | -201 | -637 | -911 | — | — | — | — | — | |
| Net Income From Continuing Operations | -334 | -201 | -637 | -911 | — | — | — | — | — | |
| Net Income | -334 | -201 | -637 | -911 | — | — | — | — | — | |
| EPS (Recurring) | -0.52 | -0.30 | -0.96 | -1.47 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.52 | -0.30 | -0.96 | -1.47 | — | — | — | — | — | |
| EPS (Diluted) | -0.52 | -0.30 | -0.96 | -1.47 | — | — | — | — | — | |
| EBITDA | 668 | 929 | 457 | -10 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 0.55 | 0.92 | 1.38 | 2.37 | — | — | — | — | — | |
| Gross Margin | 66.80 | 66.07 | 66.01 | 65.50 | — | — | — | — | — | |
| Operating Margin | -3.52 | 2.93 | -10.79 | -27.96 | — | — | — | — | — | |
| Net Margin | -13.84 | -8.19 | -24.91 | -34.65 | — | — | — | — | — | |
| Shares Outstanding | 639 | 673 | 694 | 672 | — | — | — | — | — | |
| Market Capitalization | 1,336 | 2,248 | 3,526 | 6,223 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Cornick Kenneth L. | Director | Aug 07 '26 | Buy | 1.85 | 250,000 | 462,500 | 2,000,000 | Aug 10 |
| Cornick Kenneth L. | Director | Aug 06 '26 | Buy | 1.86 | 650,000 | 1,209,000 | 1,750,000 | Aug 10 |
| Snyder Andrew Miles | Director | Aug 03 '26 | Sale | 1.94 | 2,489,618 | 4,829,859 | 3,856,597 | Aug 05 |
| Veinstein Bar | President, A&G | Dec 01 '25 | Sale | 3.74 | 309,902 | 1,159,033 | 848,811 | Dec 02 |
| Cornick Kenneth L. | Director | Nov 10 '25 | Buy | 3.45 | 100,000 | 345,000 | 1,100,000 | Nov 13 |
| Cornick Kenneth L. | Director | Nov 03 '25 | Buy | 3.52 | 225,000 | 792,000 | 1,000,000 | Nov 03 |
| Snyder Andrew Miles | Director | Oct 31 '25 | Buy | 3.33 | 1,460,000 | 4,861,800 | 2,247,510 | Nov 03 |
| Cornick Kenneth L. | Director | Oct 31 '25 | Buy | 3.38 | 500,000 | 1,690,000 | 775,000 | Nov 03 |
| Cornick Kenneth L. | Director | Aug 01 '25 | Buy | 3.74 | 165,000 | 617,100 | 275,000 | Aug 05 |
| Samson James Gordon | President, IP | Jul 01 '25 | Sale | 4.53 | 100,000 | 453,000 | 1,271,103 | Jul 02 |
| Snyder Andrew Miles | Director | Mar 14 '25 | Buy | 4.17 | 237,176 | 989,024 | 787,510 | Mar 18 |
| Bomba Jane L Okun | Director | Mar 12 '25 | Buy | 4.03 | 49,750 | 200,493 | 49,750 | Mar 14 |
| Pritchett Wendell E. | Director | Mar 03 '25 | Buy | 4.38 | 22,857 | 100,114 | 71,835 | Mar 05 |
| SAHA SAURABH | Director | Mar 03 '25 | Buy | 4.36 | 58,275 | 254,079 | 82,016 | Mar 05 |
| Angelakis Michael J | Director | Nov 22 '24 | Buy | 5.19 | 765,000 | 3,970,350 | 3,465,000 | Nov 22 |